We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 354

Federal court upholds glaucoma drug patents and enjoins generics

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 1 2011

A federal court in Texas has determined that four combination glaucoma drug patents held by Allergan Inc. were valid and that generic drug makers infringed the patents by seeking Food and Drug Administration (FDA) approval to sell their generic versions under an abbreviated new drug application

Moody’s claims “the worst is over” for pharmaceutical companies facing patent cliff

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

Moody’s Investor Services has reportedly revised its outlook for the global pharmaceutical industry and upgraded it to stable, apparently anticipating that earnings will rebound in 2013 with the slowdown in patent expirations, characterized by many industry observers as the “patent cliff.”

FDA brings successful enforcement actions against dietary supplement makers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 1 2012

The U.S. Food and Drug Administration (FDA) has obtained a permanent injunction against Truman Berst who sells, as Alternative Health & Herbs Remedies, herbs and dietary supplements with disease-treatment claims

Federal Courts of Appeals conflict over validity of pay-for-delay deals

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 2 2012

The Third Circuit Court of Appeals issued a ruling in mid-July that found “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade,” thus supporting the Federal Trade Commission’s (FTC’s) view that pay-for-delay deals that settle patent disputes between name-brand pharmaceutical companies and their generic drug competitors violate antitrust law

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."

EC scientific committee seeks input on nanosilver safety

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 3 2012

The European Commission’s (EC’s) Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) is seeking information on the health and environmental effects of nanosilver particles used in medical and consumer products

Biotech jobs post significant increase in Q1 of 2012

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 17 2012

According to the number of advertised openings in the biotech sector appearing in online job databases, the pace of hiring in the first quarter of 2012 has significantly overtaken the last quarter of 2011

Federal Ccircuit panel returns to Gore-Tex graft dispute, clarifies willfulness standard for enhanced damages

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 21 2012

The Federal Circuit Court of Appeals has vacated parts of its February 2012 decision in a long-running patent dispute over a prosthetic vascular graft and remanded the matter for the district court to address the objective prong of the willfulness standard and reconsider its denial of W.L. Gore’s motion for judgment as a matter of law of no willful infringement. Bard Peripheral Vascular, Inc. v. W.L. Gore & Assoc., Inc., No. 2010-1510 (Fed. Cir., decided June 14, 2012

Grifols acquires 51 percent stake in Araclon Biotech

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 29 2012

Grifols, a Spanish plasma-product manufacturer specializing in the hospitalpharmaceutical sector, has announced that it has acquired 51 percent of the equity of Zaragoza-based Araclon Biotech, a company spun off from the University of Zaragoza in 2004 to develop therapies and diagnostics for Alzheimer’s disease

Presidential bioethics panel to examine genome privacy

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 19 2012

The Presidential Commission for the Study of Bioethical Issues is seeking public comments “on the ethical issues raised by the ready availability of large-scale human genome sequence data, with regard to privacy and data access and the balancing of individual and societal interests.”